Prostate cancer treatment that complied with nationally endorsed quality measures did not produce clinically relevant changes in patients’ reported outcomes, according to an AHRQ-funded study. The study included 2,600 men treated with prostate cancer therapies including surgery, radiation and active surveillance. Researchers explored whether their care complied with six nationally endorsed quality measures designed to boost effective and efficient care. Compliance ranged from 64 percent to 88 percent. Patients rated their health-related quality of life, satisfaction and treatment-related complications in the first 12 months following treatment. Researchers did not find clinically meaningful improvement in functional outcomes, satisfaction scores or treatment-related complication rates associated with adherence to the quality measures. Study authors recommended further study to identify quality measures that correlate better with patient-centered outcomes. “Impact of Adherence to Quality Measures for Localized Prostate Cancer on Patient-reported Health-related Quality of Life Outcomes, Patient Satisfaction, and Treatment-related Complications” appeared in the August issue of Medical Care. Access the abstract.
Med Care. 2016 Aug;54(8):738-44. doi: 10.1097/MLR.0000000000000562.
Impact of Adherence to Quality Measures for Localized Prostate Cancer on Patient-reported Health-related Quality of Life Outcomes, Patient Satisfaction, and Treatment-related Complications.
Sohn W1, Resnick MJ, Greenfield S, Kaplan SH, Phillips S, Koyama T, Goodman M, Hamilton AS, Hashibe M, Hoffman KE, Paddock LE, Stroup AM, Wu XC, Penson DF, Barocas DA.